Answers are grounded in this paper and cite their sources.
Case report shows hemin therapy slows kidney disease progression in a woman with acute intermittent porphyria, suggesting therapeutic potential.
Acute intermittent porphyria (AIP) is a condition characterized by the neurotoxic accumulation of δ-aminolevulinic acid and porphobilinogen. However, chronic kidney disease is an under-recognized complication. A 50-year-old woman experienced recurrent abdominal pain with repeated acute kidney injury and hyponatremia, resulting in a rapid decline in renal function. Marked elevations of both metabolites, as well as her genetic mutation, confirmed AIP. The administration of hemin markedly decreased the frequency of porphyria attacks and significantly attenuated the annual estimated glomerular filtration rate decline. Although the patient eventually developed end-stage kidney disease, hemin treatment slowed the progression of renal failure.
No takes yet. Share an insight, caveat, or question.
Ishimura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: